Cytovation
Next generation immunotherapy for cancer treatment
Cytovation AS is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class tumorolytic agent targeting the cell membrane of tumor cells.
The company is a spin-off from the University of Bergen (Norway), the city where it is headquartered.
In 2021 Cytovation entered into a clinical trial collaboration and supply agreement with MSD to evaluate the safety and efficacy of CyPep-1 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy. The Phase II trial is scheduled to start early 2022.
Other companies we believe in
CardioSignalDigital biomarkers for heart diseases
FarmInsectAccelerating the transition toward sustainable animal feed
OysterPerformance cooling technology
ClimateViewAccelerating cities’ transition to net zero economies
1XCreating humanoid robots with practical, real-world applications to augment the global labor force
EvyonMaximizing the value of every battery
NoFenceThe world’s first virtual fence for livestock
GruntEnabling better data transparency
CMR SurgicalHigh precision surgery through robotics
Salient EnergyPowering the clean energy revolution with zinc-ion batteries
PowallEnhancing battery life through nanotechnology
Hallgruppen Flexible storage halls and relocatable structures
Antec BiogasAccelerating biogas production
Standard BioTurning biowaste into valuable products
PickataleMaking reading for children fun and easy
DolphitechNext generation ultrasonic platform for non-destructive testing
XerisMaking product information more accessible
Turbulent FluxMonitor your production to reduce well testing frequency
Wrepit Enabling anyone to create inspiring, accessible, written content
Subscribe
Stay in the loop - sign up for our newsletter